

# Selective Small Molecule Inhibitors of NOX2

Jaideep Saha, Ph.D

Wipf Group Topic Seminar  
17<sup>th</sup> November, 2012

# Contents

- ✓ Reactive Oxygen Species (ROS)
- ✓ Structure and Function of NOX Enzyme Family
- ✓ Prior Art of NOX Inhibitor Development
- ✓ Our Approach to Find a Selective NOX2 Inhibitor
- ✓ Conclusions and Outlook

# Reactive Oxygen Species (ROS)

## Radicals

$O_2^{\cdot-}$	Superoxide
$HO^{\cdot}$	Hydroxyl
$ROO^{\cdot}$	Peroxyl
$RO^{\cdot}$	Alkoxy
$HOO^{\cdot}$	Hydroperoxyl


## Non-Radicals

$H_2O_2$	Hydrogen Peroxide
$HOCl$	Hypochlorous Acid
$^1O_2$	Singlet Oxygen
$O_3$	Ozone
$ONOO^-$	Peroxynitrite



*ROS are oxidants generated from metabolism of molecular oxygen.*

*Toxicology. 2000, 149, 43-50.*

## Reactive Oxygen Species (ROS)



### Equations:



### Facts:

- ✓ *Superoxide anion radical is the precursor of most ROS in the cell*
- ✓ *Removal of H<sub>2</sub>O<sub>2</sub>: It's a substrate for catalase and glutathione (GSH) peroxidase and converted to O<sub>2</sub> and H<sub>2</sub>O. Its converted by myeloperoxidase (MPO) in neutrophils to HOCl; a strong oxidant that act as a bactericidal agent in phagocytic cell.*
- ✓ *H<sub>2</sub>O<sub>2</sub> catalyzed by Fe<sup>2+</sup> to produce OH• Which react with any biological molecule RH.*

Nat Rev Immunol. 2004, 4, 181


## Half life of ROS

Hydroxyl radical	⇒	<i>nanoseconds</i>
Superoxide anion		
Singlet Oxygen	⇒	<i>microseconds</i>
Alkoxy radical		
Peroxynitrite	⇒	<i>milliseconds</i>
Peroxy radicals	⇒	<i>seconds</i>
Hydrogen peroxide		
Organic Hydroperoxides	⇒	<i>minutes</i>
Hypochlorous acid		

*Toxicology*. **2000**, 149, 43-50.

# ROS mediated damages

## ROS




*Crit Rev. Toxicol.* 1993, **23**, 21-48

# Consequences of thiol oxidation


## Formation of mixed sulfide bonds

*Protein-protein linkages (RS-SR)*

*Protein-GSH linkages (RS-SG)*



## Protein targets for ROS



Alteration in 2° and 3° structure

Increased susceptibility to proteolysis

*Toxicology.* **2000**, 149, 43-50.

## *Paradigm of understanding the role of ROS*

### *Early assumptions.....*

- ✓ Due to early discovery of enzymes (SOD, catalase and peroxidase) over past three decades, a general assumption was ROS are produced accidentally In the cell.
- ✓ ROS were considered as harmful but unavoidable consequences of aerobic cellular process.
- ✓ SOD and other catabolic enzymes are evolved to protect cell from accidental production of ROS.
- ✓ Major Source: Mitochondria and NOX of phagocytes during oxidative burst.

### *Current understanding.....*

- ✓ Enzymes with sole biochemical function of producing ROS have discovered recently. It indicates that catabolic enzymes are only to regulate ROS level in cells.
- ✓ more elaborate role for regulated level of ROS has been attributed to intracellular signaling pathways

*Nat Rev Immunol.* 2004, **4**, 181



## How cell regulates ROS level?


### Cellular Antioxidants:

#### Small molecules.

- ✓ Water soluble: Glutathione, uric acid, ascorbate ( Vit. C)
- ✓ Lipid soluble :  $\alpha$ -tocopherol (Vit. E),  $\beta$ -carotene, coenzyme Q


#### Proteins.

- ✓ Intracellular: SOD (I & II), glutathione peroxidase, catalase
- ✓ Cell membrane : SOD (III), plasma proteins (eg, albumins)
- ✓ Extracellular : phospholipid hydroperoxide GPx (PHGPx)



[http://www.rndsystems.com/literature\\_MiniReviewsAll.reactive](http://www.rndsystems.com/literature_MiniReviewsAll.reactive) oxygen species


## *Oxidative Stress*



*An Imbalance favoring ROS generated to the antioxidants present in the cell*


*Experimental Physiology. 1997, 82, 291-295*

# Endogenous sources of ROS





[www.unc.edu/courses/2008fall/envr/430/001/Rusyn3ROS](http://www.unc.edu/courses/2008fall/envr/430/001/Rusyn3ROS)

## *ROS generation in mitochondria*



*Free Radic. Biol. Med.* 2011, **51**, 1271

## Cytoplasmic sources of ROS: Xanthine oxidase



*Free Radic. Biol. Med.* 2010, **48**, 493



## *NADPH oxidases (NOX)*

- ✓ NADPH oxidase activity was first described in liver microsomal isolates and bacteria In 1963.
- ✓ Until 1990, the phagocyte NADPH oxidase was only known for the “deliberate” generation of ROS (*non-mitochondrial*) in mammalian cells that catalyses the *respiratory burst*. The oxidase consist of the catalytic subunit gp91phox (otherwise known as NOX2).
- ✓ During 1990s, other sources of ROS was suspected to be a flavoproteins that is similar to gp91phox. In 1999, the first of the NOX homologues of gp91phox was describes as NOX1.
- ✓ Currently the total number of enzymes in this family is increased to seven; NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1 and DUOX2.

*Nat Rev Immunol.* 2004, **4**, 181

## *NADPH oxidases (NOX)*


- ✓ NOX's are membrane integrated proteins. No crystal structure is available
- ✓ NOX isoforms differ in tissue distribution, subunit requirement, domain structure and mechanism of activation.




*Schematic representation of common NOX features*

*Free Radic. Biol. Med.* 2011, **51**, 1271



## Structure of some related coenzymes



NADP<sup>+</sup>




NADPH



NAD<sup>+</sup>




*Transmembrane topology and domain structure of NOX & DUOX enzymes*



*Nat Rev Immunol.* 2004, **4**, 181

## *Subunit requirements in the active NOX complexes*




Three molecular triggers that initiate cell activation in presence of microorganism or inflammatory mediators:

- a. *Protein phosphorylation*
- b. *Lipid metabolism*
- c. *Guanine nucleotide exchange on RAC.*

*Free Radic. Biol. Med.* 2011, **51**, 1271

*ROS generation by assembly of Phox regulatory proteins in phagocytes*



Nat Rev Immunol. 2004, 4, 181

## ***NOX Inhibitors***

### *Overview:*

Discovery of new homologues of NADPH oxidases has stimulated the interest to target this family of enzyme as potential therapeutic agent.

The majority of the inhibitors were indentified earlier were based on their ability to block the neutrophil oxidative burst mediated by phagocyte oxidase (ie, NOX2).

Early NOX inhibitors were limited by several factors; more importantly, The inhibitors often were not specific for NOX, either block upstream pathways or inhibit other targets along with NOX.

**Specificity of action is a major challenge in the NOX field in general !**

## *Two-way Challenge*

***To identify the isoform-specific NOX inhibitor.***

*Isoforms share high percentages of residues*

*NOX1/ NOX2 – 60%*


*NOX2/ NOX4 – 39%*

*Enzymes are membrane-bound, no crystal structure available.*

*Existing antibodies are not useful*

***Proper measurement of the NOX activity using selective probes (colorometric, fluorescent or chemiluminescent) in the assay.***

## *Challenges for precise measurement of NOX activity*



### ***Removal of ROS versus true enzyme activity***

Many chemical probes detect only a specific ROS; decrease in the signal may reflect a decrease in the availability of that species through ROS scavenging or metabolism.

### ***Inhibition through indirect pathways***

Detectable NOX activity may be decreased through indirect or non-specific pathways; interfering with cell signaling pathways, physical disruption of the membrane or block pathways to NOX activation.

### ***Non specificity or interference with the assay***


Many of the assay are based on detecting the free radical species. In some cases the ROS generated may not be detected because of the interfering reaction between the inhibitor and the detection probe.

***Often two or more different methods are used to confirm the effectiveness and specificity of an inhibitor!***

*Antioxid Redox Signaling*, 2009, **11**, 2535

## Criteria for selecting a NOX inhibitor In Vitro

### Flow Chart




*Antioxid Redox Signaling*, 2009, **11**, 2535

11.17.2012<sub>23</sub>

## *Chemical probes and tools in the assay for ROS detection/measurement*

### *Fluorescence*






## *Chemical probes and tools in the assay for ROS detection/measurement*

*EPR: Electron Paramagnetic resonance*

Advantages: This method enables not only detection but identification of the radical.

Disadvantages: The success of the detection depends on the steady state concentration of the reactive species, which in reality is often low.

*Chemiluminescence:*



**Advantages**


- ✓ Light emission is generated from a reaction, No source of excitation, hence excellent sensibility and detection limit (no noise or scatter).
- ✓ Simple, robust and inexpensive instrumentation
- ✓ suitable for both batch and flow analytical technique.

**Disadvantages**

- ✓ some chemiluminescent probes tends to generate ROS.


**Chemical probes:** Luminol, Lucigenin, L012

## Mechanism for Luminol Luminescence




*Biochemistry (Moscow)*, 2009, **49**, 341-388

## Lucigenic dependent chemiLuminescence



### Other superoxide sensitive luminescence probes



NMA + hν

*Biochemistry (Moscow)*, 2009, **49**, 341-388


# NOX Inhibitors

## *Direct inhibitors of the NOX catalytic unit*

- a. Measurement of ROS production
- b. Oxygen consumption
- c. Viability
- d. Exclusion of a predominant scavenging agent
- e. NOX inhibition in cell free assay

## *Indirect inhibitors of the NOX catalytic unit*

**Prior art:**



***Diphenyleneiodonium (DPI)***

ROS Inhibition :  $IC_{50} = 0.90 \mu\text{M}$  for neutrophil NOX2.

Viability : No cell toxicity at efficient concentration

Scavenging : Inhibits completely X/XO, but no scavenging activity.

Membrane assay : NOX2/NOX4


Others : All NOX enzymes are inhibited in submicromolar range

$IC_{50} = 0.2 \mu\text{M}$  (NOX 4)

$IC_{50} = 0.30 \mu\text{M}$  (NOX5).


Inhibitors of all flavin-containing proteins and many other non specific activities.


*Antioxid Redox Signaling*, 2009, **11**, 2535



***Diphenyleneiodonium (DPI)***

- ✓ Inhibit all NOX and DUOX isoforms in submicromolar concentration.
- ✓ Used widely to provide evidence of NOX activity in tissue.
- ✓ DPI is useful tools for studying NOX enzymes in vitro but not a drug candidate due to irreversible binding, off target effects, low solubility.
- ✓ Mechanism of action:





***Phenylarsenic oxide (PAO)***

ROS Inhibition :  $IC_{50} = 0.50 \mu\text{M}$  for PMA-activated neutrophils


Viability : No cell toxicity after 30 min incubation

Scavenging : ND

Membrane assay : NOX2, other NOX's not determined

Comments : No inhibition of protein kinases at concentration used

- ✓ PAO is ineffective once the oxidase complex is formed. It suggests that it blocks one active site/unit leading to the assembly
- ✓ PAO is known to interact with vicinal cysteine residue, which is only accessible in the resting set of the NOX subunit.
- ✓ A potential NOX2 specific inhibitor as this isoform contains two neighboring Cys residue.
- ✓ Inhibitory activity can be reversed by adding a vicinal dithiol competitor.





*Eur. J. Biochem.* 1998, **251**, 649-658








## Cell-free screening for NOX inhibitors

This method is based on blockage of the cytosolic subunits required for Nox2 Activation.




*Chemistry & Biology*. 2012,**19**, 752-763

## Assay Results

Compound	Structure	EC <sub>50</sub> (μM) for Inhibition of Nox Isoform Activity in Whole Cell Assays, and EC <sub>50</sub> (μM) in Assay Controls					
		Nox1	Nox2	Nox4	Nox5	X/XO Activity	H <sub>2</sub> O <sub>2</sub> Activity
Ebselen		0.15	0.5	ns	0.7	ns	ns
Thr101		3	0.3	8	8	ns	8
JM-87a		1.5	0.5	ns	4	ns	ns
TG4-193		0.3	0.3	ns	1.7	6	30
JM-77b		6.3	0.4	ns	17	5	ns


*Chemistry & Biology*. 2012,**19**, 752-763

## Small molecule NOX inhibitors from pharmaceutical companies




N-(1-cycloheylethyl)-4-phenylphtalazin-1-amine


(Mitsubishi)



Compound C  
(Mitsubishi)




Tetrahydroindoles  
(Genkyotex)




VAS2870


(Vasopharm)




S17834  
(Servier)



Pyrazolo pyridine  
(Genkyotex)



Pyrazolo pyrimidines  
(Shionogi)



Pyrazolo pyridine  
(Genkyotex)

# Genkyotex pipeline



HOME

COMPANY

PRODUCTS

SCIENCE

NEWS & EVENTS

INVESTORS

CONTACT

## Targeting NOX to treat oxygen-radical mediated diseases

→ Learn more  
about our products

→ Discover our  
core technology

➤ A new NOX4/NOX1 inhibitor is in  
lead optimization.

➤ NOX2/1 is in hit to lead  
development



<http://www.genkyotex.com/index.php?rubID=24>

### → Latest News


**Geneva, Switzerland and Archamps, France, November 2, 2012.** Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

[View press release](#)


## Genkyotex library for NOX4/NOX1 inhibitors




NOX1  $K_i = 119 \pm 20$  nM  
 NOX2  $K_i = 365 \pm 5$  nM  
 NOX4  $K_i = 87 \pm 8$  nM  
 NOX5  $K_i = 360 \pm 74$  nM




NOX1  $K_i = 218 \pm 39$  nM  
 NOX2  $K_i = 645 \pm 75$  nM  
 NOX4  $K_i = 144 \pm 22$  nM  
 NOX5  $K_i = 670 \pm 30$  nM




NOX1  $K_i = 184 \pm 24$  nM  
 NOX2  $K_i = 780 \pm 170$  nM  
 NOX4  $K_i = 116 \pm 9$  nM  
 NOX5  $K_i = 690 \pm 10$  nM



NOX1  $K_i = 212 \pm 51$  nM  
 NOX2  $K_i = 820 \pm 150$  nM  
 NOX4  $K_i = 131 \pm 6$  nM  
 NOX5  $K_i = 690 \pm 60$  nM



NOX1  $K_i = 217 \pm 18$  nM  
 NOX2  $K_i = 510 \pm 20$  nM  
 NOX4  $K_i = 93 \pm 11$  nM  
 NOX5  $K_i = 610 \pm 40$  nM



NOX1  $K_i = 173 \pm 14$  nM  
 NOX2  $K_i = 433 \pm 19$  nM  
 NOX4  $K_i = 156 \pm 11$  nM  
 NOX5  $K_i = 490 \pm 67$  nM

*Bioorg. Med. Chem.* 2011, **19**, 6989

## *Acknowledgement*

- Professor Peter Wipf.
- Professor Patrick J. Pagano
- Dr. Erin M. Skoda
- Dr. Eugenia Cifuentes-Pagano
- Wipf group members-past and present
- NIH (RO1HL079207)
- NIH (PO1HL103455-02)

